EXEL vs. JAZZ: Exelixis vs. Jazz Pharmaceuticals Stock Comparison
How do Exelixis (EXEL) and Jazz Pharmaceuticals (JAZZ) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Exelixis (EXEL) and Jazz Pharmaceuticals (JAZZ) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but EXEL is classified in Biotechnology while JAZZ is classified in Pharmaceuticals.
| Profile Item | EXEL | JAZZ |
|---|---|---|
| Name | Exelixis Inc. | Jazz Pharmaceuticals plc |
| Country/Region | United States | Ireland |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Pharmaceuticals |
| GICS Sub-Industry | Biotechnology | Pharmaceuticals |
| Market Capitalization | 16.98 billion USD | 15.07 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | April 17, 2000 | June 1, 2007 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | EXEL | JAZZ |
|---|---|---|
| Total Return (1Y) | 74.98% | 84.44% |
| Total Return (3Y, Annualized) | 50.33% | 27.57% |
| Total Return (5Y, Annualized) | 31.10% | 12.88% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | EXEL | JAZZ |
|---|---|---|
| Volatility (1Y, Annualized) | 34.17% | 38.74% |
| Beta (5Y) | 0.41 | 0.33 |
| Max Drawdown (5Y) | -35.41% | -42.03% |
| Avg. Volume (3M) | 2.33M | 878.80K |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | EXEL | JAZZ |
|---|---|---|
| Sharpe Ratio (1Y) | 2.07 | 2.07 |
| Sortino Ratio (1Y) | 3.23 | 4.14 |
Profitability
ROE (TTM)
Exelixis (EXEL) at 44.32% sits in the top ROE quartile, while Jazz Pharmaceuticals (JAZZ) at 5.05% is closer to the peer norm — stronger capital efficiency for EXEL.
EXEL
Pharmaceuticals, Biotechnology & Life Sciences industry group
44.32%
- Max
- 109.18%
- EXEL
- 44.32%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.05%
- Max
- 109.18%
- Q3
- 6.23%
- JAZZ
- 5.05%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Exelixis (EXEL) at 35.45% converts revenue to bottom-line profit above its industry’s benchmark range, while Jazz Pharmaceuticals (JAZZ) at 4.37% keeps roughly the typical share for its industry.
EXEL
Pharmaceuticals, Biotechnology & Life Sciences industry group
35.45%
- EXEL
- 35.45%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.37%
- Max
- 18.05%
- Q3
- 4.78%
- JAZZ
- 4.37%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Exelixis (EXEL) at 40.75% and Jazz Pharmaceuticals (JAZZ) at 30.17% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
EXEL
Pharmaceuticals, Biotechnology & Life Sciences industry group
40.75%
- Max
- 83.12%
- EXEL
- 40.75%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
30.17%
- Max
- 83.12%
- JAZZ
- 30.17%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | EXEL | JAZZ |
|---|---|---|
| ROE (TTM) | 44.32% | 5.05% |
| ROA (TTM) | 23.52% | 6.92% |
| Net Margin (TTM) | 35.45% | 4.37% |
| Operating Margin (TTM) | 40.75% | 30.17% |
| Gross Margin (TTM) | 96.26% | 91.10% |
Growth
Revenue Growth
Both Exelixis (EXEL) at 6.98% and Jazz Pharmaceuticals (JAZZ) at 4.88% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Exelixis (EXEL) at 57.95% is around its peer norm for EPS growth, while Jazz Pharmaceuticals (JAZZ) at -167.51% drops into the bottom quartile, signaling weaker earnings momentum.
Growth Metrics
| Metric | EXEL | JAZZ |
|---|---|---|
| Revenue Growth (YoY) | 6.98% | 4.88% |
| Revenue Growth (3Y CAGR) | 12.93% | 5.26% |
| EPS Growth (YoY) | 57.95% | -167.51% |
| EPS Growth (3Y CAGR) | 70.59% | -- |
Financial Strength
Current Ratio (MRQ)
Exelixis (EXEL) at 3.21 keeps current ratio within its industry’s typical mid-range, while Jazz Pharmaceuticals (JAZZ) at 1.82 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for JAZZ.
EXEL
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.21
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- EXEL
- 3.21
- Q1
- 2.47
- Min
- 0.10
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.82
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- JAZZ
- 1.82
- Min
- 0.10
Debt / Equity (MRQ)
Exelixis (EXEL) at 0.09 carries an industry-typical debt-to-equity mix, while Jazz Pharmaceuticals (JAZZ) at 1.35 uses more debt funding than most peers.
EXEL
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.09
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- EXEL
- 0.09
- Q1
- 0.02
- Min
- 0.00
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.35
- Max
- 1.42
- JAZZ
- 1.35
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | EXEL | JAZZ |
|---|---|---|
| Current Ratio (MRQ) | 3.21 | 1.82 |
| Debt / Equity (MRQ) | 0.09 | 1.35 |
| Net Debt / EBITDA | -0.71 | 1.39 |
Dividends
Dividend Yield (TTM)
Neither Exelixis (EXEL) nor Jazz Pharmaceuticals (JAZZ) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
EXEL
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- EXEL
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- JAZZ
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Exelixis (EXEL) nor Jazz Pharmaceuticals (JAZZ) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
EXEL
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- EXEL
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- JAZZ
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | EXEL | JAZZ |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Exelixis (EXEL) at 20.83 is near its industry’s usual P/E ratio, while Jazz Pharmaceuticals (JAZZ) at 69.46 sits in the richer quartile — JAZZ needs stronger growth or earnings quality to justify the premium.
EXEL
Pharmaceuticals, Biotechnology & Life Sciences industry group
20.83
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- EXEL
- 20.83
- Q1
- 13.30
- Min
- 0.07
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
69.46
- Max
- 85.34
- JAZZ
- 69.46
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Exelixis (EXEL) at 6.80 and Jazz Pharmaceuticals (JAZZ) at 3.19 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
EXEL
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.80
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- EXEL
- 6.80
- Q1
- 3.01
- Min
- 0.01
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.19
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- JAZZ
- 3.19
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Jazz Pharmaceuticals (JAZZ) at 3.59 is valued about in line with its industry on P/B ratio, while Exelixis (EXEL) at 9.28 carries an above-peer premium to book — EXEL is pricier on assets.
EXEL
Pharmaceuticals, Biotechnology & Life Sciences industry group
9.28
- Max
- 13.53
- EXEL
- 9.28
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.59
- Max
- 13.53
- Q3
- 6.54
- JAZZ
- 3.59
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | EXEL | JAZZ |
|---|---|---|
| P/E Ratio (TTM) | 20.83 | 69.46 |
| P/S Ratio (TTM) | 6.80 | 3.19 |
| P/B Ratio (MRQ) | 9.28 | 3.59 |
| Free Cash Flow Yield (TTM) | 4.47% | 11.16% |